Biogen shares deflate as it gives up on sale

After ratcheting up expectations of a takeover and a hefty premium for stockholders, Biogen Idec pulled the rug out from under investors with its announcement that it will go it alone. The market's retribution was swift. Biogen stock plunged more than 27 percent, dropping $21 of the $75.88 price on Wednesday's close. The fallout was also quick, spreading to Biogen Idec's collaborator, Elan. Elan experienced its worst single-day drop in 18 months, shedding 13 percent of its value as investors took a nanosecond to consider that the Irish company will no longer stand to gain from Biogen's sale. A Biogen buyout would have allowed Elan to acquire all rights to their MS drug, Tysabri. Analysts started speculating that the biotech had found buyout talks tough going, with its collaborations involving Elan and Genentech complicating any talks with Big Pharma. Biogen launched its review after Carl Icahn took a stake in the company and began talking buyout.

- see Biogen's release on the decision
- here's the AP report on the about face

Related Articles:
Is Big Pharma souring on Biogen deal? Report
Sources: Biogen gets bidders, with Pfizer in lead. Report
What's Biogen Idec really worth to Big Pharma? Report
Will Big Pharma buy Biogen Idec? Report
Biogen Idec in play after Icahn makes his move. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.